Search | Clinical Trials Finder

Conditions: Colorectal Cancer
Interventions: Temozolomide + Olaparib; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Food-drug Interaction
Interventions: Licorice, Alprazolam 2 MG, Caffeine 100 MG, Tolbutamide 250 mg, Dextromethorphan 30mg; Dietary Supplement · Drug
Lead sponsor: University of Illinois at Chicago; Other
Eligibility: 40 Years to 79 Years · Female only
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Bone Cancer, Ewing's Sarcoma
Interventions: Irinotecan, Vincristine, Temozolomide, Doxorubicin, Cytoxan, Pegfilgrastim; Drug
Lead sponsor: Stanford University; Other
Eligibility: 13 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Stanford, California

Conditions: Esophageal Squamous Cell Carcinoma (ESCC)
Interventions: Tislelizumab, Paclitaxel, Docetaxel, Irinotecan; Drug
Lead sponsor: BeiGene; Industry
Eligibility: 18 Years and older
Enrollment: 512 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Detroit, Michigan • Toledo, Ohio

Conditions: Endometrial Cancer
Interventions: carboplatin, docetaxel, radiation therapy; Drug · Radiation
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: 18 Years and older · Female only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Louis Park, Minnesota

Conditions: Glioblastoma
Interventions: GammaTile®, External Beam Radiation Therapy, Temozolomide; Device · Radiation · Drug
Lead sponsor: GT Medical Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 766 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 9
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Baltimore, Maryland + 6 more

Conditions: Colonoscopy
Interventions: patient control of pump, anesthesiologist controlled sedation; Other
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 90 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Acute Myeloid Leukemia
Interventions: Minnelide; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Human Immunodeficiency Virus Type 1
Interventions: TMC278 25 mg, TMC278 75 mg, TMC278 150 mg, Efavirenz, Non-nucleoside reverse transcriptase inhibitor (NRTIs); Drug
Lead sponsor: Tibotec Pharmaceuticals, Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 368 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 9
States / cities: Beverly Hills, California • Washington D.C., District of Columbia • Orlando, Florida + 6 more

Conditions: Prostate Cancer
Interventions: Grape Seed Extract; Dietary Supplement
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Aurora, Colorado • Fort Collins, Colorado

Conditions: Plaque Psoriasis
Interventions: Apremilast, Placebo, Topical or Phototherapy Therapy; Drug · Other
Lead sponsor: Amgen; Industry
Eligibility: 18 Years and older
Enrollment: 413 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 19
States / cities: Phoenix, Arizona • Hot Springs, Arkansas • Bakersfield, California + 15 more

Conditions: Acute Myeloid Leukemia
Interventions: PF-06747143, Cytarabine, Daunorubicin, Azacitidine, Decitabine; Biological · Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 4
States / cities: Tucson, Arizona • Chicago, Illinois • Winston-Salem, North Carolina

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
Interventions: Itraconazole, PKC412; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • New York, New York

Conditions: Leukemia, Myelodysplastic Syndromes
Interventions: aldesleukin, filgrastim, natural killer cell (NK) therapy, cyclophosphamide, cyclosporine, fludarabine phosphate, methylprednisolone, mycophenolate mofetil, Umbilical Cord Blood Transplantation (UCBT), Total body irradiation (TBI); Biological · Drug · Procedure + 1 more
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 45 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Hypertension
Interventions: Aliskiren (6.25/12.5/25 mg), Aliskiren (37.5/75/150 mg), Aliskiren (150/300/600 mg); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 17 Years
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 23
States / cities: Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 19 more

Conditions: Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Acute Myelogenous Leukemia (AML)
Interventions: Subcutaneous (SC) Azacitidine, Oral Azacitidine; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years and older
Enrollment: 133 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2016
U.S. locations: 18
States / cities: Gainesville, Florida • Chicago, Illinois • Indianapolis, Indiana + 15 more

Conditions: Breast Neoplasm
Interventions: epirubicin, cyclophosphamide, docetaxel, trastuzumab; Drug
Lead sponsor: Accelerated Community Oncology Research Network; Other
Eligibility: 18 Years and older · Female only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 7
States / cities: Miami, Florida • Augusta, Georgia • Macon, Georgia + 4 more

Conditions: Postoperative Pain
Interventions: HTX-011, Bupivacaine HCl, Saline placebo, Luer-lock applicator, Vial access device; Drug · Device
Lead sponsor: Heron Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 418 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 22
States / cities: Florence, Alabama • Sheffield, Alabama • Phoenix, Arizona + 18 more

Conditions: Breast Cancer
Interventions: Paclitaxel, Docetaxel, Capecitabine; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: Female only
Enrollment: 603 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Pancreatic Adenocarcinoma
Interventions: Pimasertib, Gemcitabine, Placebo; Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 141 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2015
U.S. locations: 1
States / cities: Rockland, Massachusetts

Conditions: Major Depressive Disorder
Interventions: BHV-7000; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 66
States / cities: Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 58 more

Conditions: Anklyosing Spondylitis
Interventions: Secukinumab (75 mg), Placebo, Secukinumab (150 mg); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 219 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 10
States / cities: Mesa, Arizona • Upland, California • Edina, Minnesota + 6 more

Conditions: Hot Flushes, Menopause, Premature, Obesity, Vitamin D Deficiency
Interventions: Vitamin D, Placebo; Dietary Supplement · Other
Lead sponsor: Kaiser Permanente; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 23 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Portland, Oregon

Conditions: Glioblastoma
Interventions: Radiation Therapy, Temozolomide Oral Product; Radiation · Drug
Lead sponsor: John Flickinger; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Search by objective public record fields.

TMZ + Olaparib for MGMT Hypermethylated Colorectal Cancer

Licorice Botanical Dietary Supplements - Metabolism and Safety in Women

Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Carboplatin, Docetaxel, and Radiation Therapy in Treating Patients With Stage III/IV, or Recurrent Endometrial Cancer

Beginning Radiation Immediately With GammaTile at GBM Excision Versus Standard of Care

Patient-Controlled Sedation Versus Anesthesiologist-Administered Sedation

Dose Escalation Study of Minnelide in Relapsed or Refractory Acute Myeloid Leukemia

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

A Study of Grape Seed Extract in Asymptomatic Non-Metastatic Prostate Cancer Patients With Rising PSA

Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis.

A Study Of PF-06747143, As Single Agent Or In Combination With Standard Chemotherapy In Adult Patients With Acute Myeloid Leukemia

PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome (CPKC412A2104 Core); and PKC412 in Participants With Acute Myeloid Leukemia or With Myelodysplastic Syndrome With Either Wild Type or Mutated FMS-like Tyrosine Kinase 3 (FLT3) (CPKC412A2104E1 and CPKC412A2104E2)

Donor Umbilical Cord Blood Natural Killer Cells, Aldesleukin and Umbilical Cord Blood Transplant in Patients With Refractory Hematologic Cancers.

Safety and Efficacy of Aliskiren in Pediatric Hypertensive Patients 6-17 Years of Age

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Subjects With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myelogenous Leukemia

Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients

Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)

Evaluation of Differing Taxanes/Taxane Combinations on the Outcome of Patients With Operable Breast Cancer

Trial of Gemcitabine With or Without MSC1936369B in Pancreatic Cancer

Long-term Safety Study of BHV-7000 in Participants With Major Depressive Disorder (MDD)

16 Week Efficacy and 5 Year Long Term Efficacy, Safety and Tolerability of Secukinumab in Patients With Active Ankylosing Spondylitis

The Role of Vitamin D in Menopause: Relationship to Menopausal Symptoms in Body Composition

Short Course Chemo-Radiation Therapy for Patients With Newly Diagnosed Glioblastoma